Every January, organisations across Europe and beyond recognise Data Protection Awareness Week, anchored around Data Protection Day on 28th January. The date marks the signing of Convention 108 in 1981 – the first legally binding international agreement on the protection of personal data, led by the Council of Europe.

More than four decades on, the principle behind Convention 108 remains unchanged: individuals have the right to trust how their data is handled. What has changed is the scale, complexity and sensitivity of the data organisations now process – particularly in regulated life-sciences environments.

For pharmacovigilance teams, data protection is not a background consideration. It is fundamental to patient safety, regulatory credibility and organisational resilience.

 

Why Data Protection Hits Differently in Pharmacovigilance:

Unlike many business functions, pharmacovigilance routinely handles:

• Sensitive personal and health data
• Information crossing borders and regulatory jurisdictions
• Inputs from multiple third parties and systems
• Long-retention datasets subject to inspection and audit

In this context, a data protection failure is rarely isolated. It has knock-on effects: inspection findings, loss of regulator confidence, reputational damage, and ultimately erosion of public trust.

This is why modern regulations – from GDPR to sector-specific guidance – emphasise accountability and demonstrable control, not just written policy.

 

From Compliance on Paper to Protection in Practice:

One of the most important evolutions in data protection regulation is the concept of “data protection by design and by default”. First introduced formally under GDPR, the idea is simple but powerful:

Data protection should be built into systems and processes from the outset – not retrofitted after issues arise.

In practice, this means organisations must be able to demonstrate:

• Who can access data, and why
• How actions are tracked and audited
• That data is minimised, not duplicated unnecessarily
• That governance is supported operationally, not manually enforced

Technology plays a critical role here – either strengthening these controls or quietly undermining them.

 

The Role of Technology: Enabler or Risk Multiplier

Automation and digital platforms are now embedded across pharmacovigilance operations. When designed well, they reduce human error, improve consistency and enhance oversight. When designed poorly, they introduce opacity, uncontrolled access and fragmented accountability.

At PharSafer, our experience across global safety operations has shaped a clear philosophy: technology should reinforce good governance, not attempt to replace it.

That thinking underpins RAPTAR – a platform designed to support compliant, inspection-ready safety processes in real-world regulated environments, whilst enabling organisations to apply their governance frameworks effectively, through:

• Access and permission controls aligned to defined roles, responsibilities, and procedural governance
• Full auditability of actions and decisions
• Workflow structures that support data minimisation
• Secure handling of safety data across integrated systems

In short, it supports organisations in doing the right thing – consistently and transparently.

 

Why This Matters Beyond Regulation

Data protection is often framed as a regulatory obligation. In reality, it is also a strategic differentiator.

Organisations that embed privacy and accountability into their operations:

• Inspire greater confidence from regulators

• Build stronger partnerships with sponsors and vendors

• Reduce operational friction during audits and inspections

• Protect the trust of patients whose data underpins everything

This is particularly important as regulatory scrutiny continues to evolve and expectations shift from what policies say to how systems actually behave.

 

A Moment to Reflect – and Act!

Data Protection Awareness Week is not about box-ticking or awareness posters. It’s an opportunity to pause and ask a harder question:

Do our systems actively support the standards we’re accountable to?

For pharmacovigilance leaders, the answer lies at the intersection of people, process and technology. Getting that balance right is not just about avoiding findings – it’s about building sustainable, trustworthy safety operations.